Drevet’s demonstrated that those who received Anti-IL6 antibody Sirukumab as an adjunct treatment for TRD and had baseline CRP levels of >6mgI-1 showed significant improvements in anhedonia rating scales compared to controls at 12 weeks. This evidence concerns the gene IL6 and treatment resistant depression.